{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:55Z","timestamp":1790960815124,"version":"4.1.0"},"reference-count":124,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw University of Technology","award":["8211104160"],"award-info":[{"award-number":["8211104160"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase are the CDK4 and CDK6 kinases, which are controlled by D-type cyclins. The CDK4\/6 kinases enable the use of these proteins as targets for anticancer therapy because they prevent the growth and the development of malignant cells by inhibiting their activity. This paper surveys the clinical trial results concerning palbociclib, the first in-class FDA-approved anticancer drug for hormone-dependent breast cancer. It discusses the therapeutic applications in breast cancer as well as in solid tumors and hematopoietic malignancies. Additionally, the paper presents an analysis of palbociclib resistance acquired during therapy and explores new approaches, such as modifications to palbociclib that enhance its desired activity or open up new therapeutic possibilities (PROTACs).<\/jats:p>","DOI":"10.3390\/molecules29225334","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:10:48Z","timestamp":1731478248000},"page":"5334","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Palbociclib as an Antitumor Drug: A License to Kill"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-5167","authenticated-orcid":false,"given":"Agnieszka","family":"\u0141upicka-S\u0142owik","sequence":"first","affiliation":[{"name":"Division of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-3572","authenticated-orcid":false,"given":"Federica","family":"Cossu","sequence":"additional","affiliation":[{"name":"National Research Council, Institute of Biophysics (IBF-CNR), Milan Unit, Via Corti, 12, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-5264","authenticated-orcid":false,"given":"Marcin","family":"Sie\u0144czyk","sequence":"additional","affiliation":[{"name":"Division of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., and Chen, C. (2020). Mechanisms of CDK4\/6 Inhibitor Resistance in Luminal Breast Cancer. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.580251"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1101\/gad.1256504","article-title":"Living with or without Cyclins and Cyclin-Dependent Kinases","volume":"18","author":"Sherr","year":"2004","journal-title":"Genes Dev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/oncolo\/oyac138","article-title":"Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib","volume":"27","author":"Wander","year":"2022","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The Role of CDK6 in Cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To Cycle or Not to Cycle: A Critical Decision in Cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The Cell Cycle: A Review of Regulation, Deregulation and Therapeutic Targets in Cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1021\/bi0009643","article-title":"On the Concentrations of Cyclins and Cyclin-Dependent Kinases in Extracts of Cultured Human Cells","volume":"39","author":"Arooz","year":"2000","journal-title":"Biochemistry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/jacsau.4c00138","article-title":"CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets","volume":"4","author":"Zhang","year":"2024","journal-title":"JACS Au"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yang, H.W., Cappell, S.D., Jaimovich, A., Liu, C., Chung, M., Daigh, L.H., Pack, L.R., Fan, Y., Regot, S., and Covert, M. (2020). Stress-Mediated Exit to Quiescence Restricted by Increasing Persistence in CDK4\/6 Activation. eLife, 9.","DOI":"10.7554\/eLife.44571"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of Sensitivity and Resistance to CDK4\/6 Inhibition","volume":"37","author":"Malumbres","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/0008-5472.CAN-20-2121","article-title":"Differential Regulation of Cancer Progression by CDK4\/6 Plays a Central Role in DNA Replication and Repair Pathways","volume":"81","author":"Dai","year":"2021","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","article-title":"A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis","volume":"24","author":"Kollmann","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a Selective Cyclin D Kinase 4\/6 Inhibitor, Preferentially Inhibits Proliferation of Luminal Estrogen Receptor-Positive Human Breast Cancer Cell Lines in Vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/ERC-10-0262","article-title":"Therapeutically Activating RB: Reestablishing Cell Cycle Control in Endocrine Therapy-Resistant Breast Cancer","volume":"18","author":"Thangavel","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","article-title":"Combination Therapies with CDK4\/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer","volume":"83","author":"Goodwin","year":"2023","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1158\/1078-0432.CCR-21-0024","article-title":"A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer","volume":"27","author":"Palmbos","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3324\/haematol.2021.279410","article-title":"Rational Drug Combinations with CDK4\/6 Inhibitors in Acute Lymphoblastic Leukemia","volume":"107","author":"Bride","year":"2022","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle Cell Lymphoma: Biology, Pathogenesis, and the Molecular Basis of Treatment in the Genomic Era","volume":"117","author":"Dreyling","year":"2011","journal-title":"Blood"},{"key":"ref_22","first-page":"1143","article-title":"Flavopiridol (L86 8275; NSC 649890), a New Kinase Inhibitor for Tumor Therapy","volume":"9","author":"Sedlacek","year":"1996","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib Prior to Chemotherapy and Atezolizumab in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial","volume":"148","author":"Daniel","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation with the CDK4\/6 Inhibitor Trilaciclib in Patients with Small-Cell Lung Cancer Receiving First-Line Chemotherapy: A Phase Ib\/Randomized Phase II Trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.2019003604","article-title":"Selective Inhibition of Ph-Positive ALL Cell Growth through Kinase-Dependent and -Independent Effects by CDK6-Specific PROTACs","volume":"135","author":"Dominici","year":"2020","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1039\/D0SC00167H","article-title":"Systematic Exploration of Different E3 Ubiquitin Ligases: An Approach towards Potent and Selective CDK6 Degraders","volume":"11","author":"Steinebach","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell Cycle Proteins as Promising Targets in Cancer Therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Afifi, N., and Barrero, C.A. (2023). Understanding Breast Cancer Aggressiveness and Its Implications in Diagnosis and Treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041375"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/BCTT.S340741","article-title":"Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where Are We Now?","volume":"15","author":"Ring","year":"2023","journal-title":"Breast Cancer Targets Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shaath, H., Elango, R., and Alajez, N.M. (2021). Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (LncRNA) Transcriptomes Identifies Novel Diagnostic LncRNA Panel for Triple-Negative Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13215350"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The Cyclin-Dependent Kinase 4\/6 Inhibitor Palbociclib in Combination with Letrozole versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1\/TRIO-18): A Randomised Phase 2 Study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/cas.12932","article-title":"Phase I Study of Palbociclib, a Cyclin-Dependent Kinase 4\/6 Inhibitor, in Japanese Patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1002\/cam4.3091","article-title":"Palbociclib-Letrozole as First-Line Treatment for Advanced Breast Cancer: Updated Results from a Japanese Phase 2 Study","volume":"9","author":"Takahashi","year":"2020","journal-title":"Cancer Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.08.012","article-title":"Palbociclib plus Letrozole versus Placebo plus Letrozole in Asian Postmenopausal Women with Oestrogen Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Primary Results from PALOMA-4","volume":"175","author":"Xu","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor\u2013Positive Early Breast Cancer: PALLET Trial","volume":"37","author":"Johnston","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40261-023-01294-3","article-title":"Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+\/HER2\u2212 Advanced Breast Cancer in Latin America for Whom Letrozole Therapy Is Deemed Appropriate","volume":"43","author":"Fein","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ajco.13653","article-title":"Palbociclib plus Letrozole as Treatment for Postmenopausal Women with Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer for Whom Letrozole Therapy Is Deemed Appropriate: An Expanded Access Study in Australi","volume":"18","author":"Loi","year":"2022","journal-title":"Asia. Pac. J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00504-z","article-title":"A Phase II Study of Palbociclib plus Letrozole plus Trastuzumab as Neoadjuvant Treatment for Clinical Stages II and III ER+ HER2+ Breast Cancer (PALTAN)","volume":"9","author":"Ademuyiwa","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sedrak, M.S., Lee, M.K., Ji, J., Satele, D.V., Freedman, R.A., Poorvu, P.D., O\u2019Connor, T., Williams, G.R., Hopkins, J.O., and Muss, H.B. (2024). Palbociclib in Adults Aged 70 Years and Older with Advanced Breast Cancer: A Phase 2 Multicenter Trial (Alliance A171601). J. Geriatr. Oncol., 15.","DOI":"10.1016\/j.jgo.2024.101813"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cristofanilli, M., Rugo, H.S., Im, S.-A., Slamon, D.J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., and Loi, S. (2021). Overall Survival (OS) with Palbociclib (PAL) + Fulvestrant (FUL) in Women with Hormone Receptor\u2013Positive (HR+), Human Epidermal Growth Factor Receptor 2\u2013Negative (HER2\u2013) Advanced Breast Cancer (ABC): Updated Analyses from PALOMA-3. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.1000"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2021.12.030","article-title":"Serum Thymidine Kinase Activity in Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer Treated with Palbociclib and Fulvestrant","volume":"164","author":"Malorni","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"PD1","DOI":"10.1158\/1538-7445.SABCS18-PD1-10","article-title":"Abstract PD1-10: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced\/Metastatic Breast Cancer: CCTG MA38 (NCT02630693)","volume":"79","author":"Parulekar","year":"2019","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.23.01940","article-title":"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4\/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor\u2013Positive\/Human Epidermal Growth Factor Receptor\u2013Negative Metastatic Breast Cancer","volume":"42","author":"Mayer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"PD1","DOI":"10.1158\/1538-7445.SABCS20-PD1-03","article-title":"Abstract PD1-03: A Phase Ib Trial of Fulvestrant + CDK4\/6 Inhibitor (CDK4\/6i) Palbociclib + Pan-FGFR Tyrosine Kinase Inhibitor (TKI) Erdafitinib in FGFR -Amplified\/ER+\/HER2-Negative Metastatic Breast Cancer (MBC)","volume":"81","author":"Mayer","year":"2021","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bagegni, N., Thomas, S., Liu, N., Luo, J., Hoog, J., Northfelt, D.W., Goetz, M.P., Forero, A., Bergqvist, M., and Karen, J. (2017). Serum Thymidine Kinase 1 Activity as a Pharmacodynamic Marker of Cyclin-Dependent Kinase 4\/6 Inhibition in Patients with Early-Stage Breast Cancer Receiving Neoadjuvant Palbociclib. Breast Cancer Res., 19.","DOI":"10.1186\/s13058-017-0913-7"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-22-2305","article-title":"Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB\/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor\u2013Positive Breast Cancer","volume":"28","author":"Tsuji","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Tejeda Za\u00f1udo, J., Barroso-Sousa, R., Jain, E., Jin, Q., Li, T., Buendia-Buendia, J.E., Pereslete, A., Abravanel, D.L., Ferreira, A.R., and Wrabel, E. (2024). Exemestane plus Everolimus and Palbociclib in Metastatic Breast Cancer: Clinical Response and Genomic\/Transcriptomic Determinants of Resistance in a Phase I\/II Trial. Nat. Commun., 15.","DOI":"10.1038\/s41467-024-45835-6"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Jerusalem, G., Prat, A., Salgado, R., Reinisch, M., Saura, C., Borrego, M.R., Nikolinakos, P., Ades, F., Filian, J., and Huang, N. (2023). Neoadjuvant Nivolumab + Palbociclib + Anastrozole for Oestrogen Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results from CheckMate 7A8. Breast, 72.","DOI":"10.1016\/j.breast.2023.103580"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant Palbociclib plus Either Giredestrant or Anastrozole in Oestrogen Receptor-Positive, HER2-Negative, Early Breast Cancer (CoopERA Breast Cancer): An Open-Label, Randomised, Controlled, Phase 2 Study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Samjoo, I.A., Hall, A., Chen, C., Nguyen, B.-N., Bartlett, M., Smith, M.L., Harbeck, N., Cappelleri, J.C., Karuturi, M., and Makari, D. (2024). A Systematic Review of Health-Related Quality of Life Outcomes in Patients with Advanced Breast Cancer Treated with Palbociclib. J. Comp. Eff. Res., 13.","DOI":"10.57264\/cer-2024-0111"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11523-024-01046-z","article-title":"Palbociclib in Older Patients with Advanced\/Metastatic Breast Cancer: A Systematic Review","volume":"19","author":"Brain","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD Final Overall Survival and Tolerability Results: Olaparib versus Chemotherapy Treatment of Physician\u2019s Choice in Patients with a Germline BRCA Mutation and HER2-Negative Metastatic Breast Cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Patel, J.M., Goss, A., Garber, J.E., Torous, V., Richardson, E.T., Haviland, M.J., Hacker, M.R., Freeman, G.J., Nalven, T., and Alexander, B. (2020). Retinoblastoma Protein Expression and Its Predictors in Triple-Negative Breast Cancer. NPJ Breast Cancer, 6.","DOI":"10.1038\/s41523-020-0160-4"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Huang, Y., Wu, H., and Li, X. (2020). Novel Sequential Treatment with Palbociclib Enhances the Effect of Cisplatin in RB-Proficient Triple-Negative Breast Cancer. Cancer Cell Int., 20.","DOI":"10.1186\/s12935-020-01597-x"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Estepa-Fern\u00e1ndez, A., Garc\u00eda-Fern\u00e1ndez, A., L\u00e9rida-Viso, A., Blandez, J.F., Galiana, I., Sancenon-Galarza, F., Orz\u00e1ez, M., and Mart\u00ednez-M\u00e1\u00f1ez, R. (2023). Combination of Palbociclib with Navitoclax Based-Therapies Enhances in Vivo Antitumoral Activity in Triple-Negative Breast Cancer. Pharmacol. Res., 187.","DOI":"10.1016\/j.phrs.2022.106628"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.2147\/CMAR.S310649","article-title":"Potential Prospect of CDK4\/6 Inhibitors in Triple-Negative Breast Cancer","volume":"13","author":"Hu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-18-0790","article-title":"Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer","volume":"25","author":"Clark","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"P4-01-02","DOI":"10.1158\/1538-7445.SABCS22-P4-01-02","article-title":"Abstract P4-01-02: Results from a Dose Escalation Phase 1b Study of Palbociclib and Avelumab in Advanced Breast Cancer in the PAveMenT Trial","volume":"83","author":"Okines","year":"2023","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Gucalp, A., Boyle, L.A., Alano, T., Arumov, A., Gounder, M.M., Patil, S., Feigin, K., Edelweiss, M., D\u2019Andrea, G., and Bromberg, J. (2020). Phase II Trial of Bicalutamide in Combination with Palbociclib for the Treatment of Androgen Receptor (+) Metastatic Breast Cancer. J. Clin. Oncol., 38.","DOI":"10.1200\/JCO.2020.38.15_suppl.1017"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Gopalan, P.K., Pinder, M.C., Chiappori, A., Ivey, A.M., Villegas, A.G., and Kaye, F.J. (2014). A Phase II Clinical Trial of the CDK 4\/6 Inhibitor Palbociclib (PD 0332991) in Previously Treated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Inactivated CDKN2A. J. Clin. Oncol., 32.","DOI":"10.1200\/jco.2014.32.15_suppl.8077"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37352","DOI":"10.18632\/oncotarget.26424","article-title":"CDK4\/6 Inhibition Stabilizes Disease in Patients with P16-Null Non-Small Cell Lung Cancer and Is Synergistic with MTOR Inhibition","volume":"9","author":"Gopalan","year":"2018","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/13543784.2022.2075341","article-title":"A Phase 1b\/2 Study of PF-06747775 as Monotherapy or in Combination with Palbociclib in Patients with Epidermal Growth Factor Receptor Mutant Advanced Non-Small Cell Lung Cancer","volume":"31","author":"Cho","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00068","article-title":"Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","volume":"3","author":"Halabi","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/PO.20.00037","article-title":"Palbociclib in Patients With Non\u2013Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","volume":"4","author":"Ahn","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Schuetze, S., Rothe, M., Mangat, P.K., Garrett-Mayer, E., Meric-Bernstam, F., Calfa, C.J., Farrington, L.C., Livingston, M.B., Wentzel, K., and Behl, D. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis. Oncol., 8.","DOI":"10.1200\/PO.24.00219"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1016\/j.annonc.2022.07.598","article-title":"469P A Phase I Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies","volume":"33","author":"Alese","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","article-title":"Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4\/6","volume":"82","author":"Sorokin","year":"2022","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"O\u2019Hara, M.H., Edmonds, C., Farwell, M., Perini, R.F., Pryma, D.A., Teitelbaum, U.R., Giantonio, B.J., Damjanov, N., Lal, P., and Feldman, M.D. (2015). Phase II Pharmacodynamic Trial of Palbociclib in Patients with KRAS Mutant Colorectal Cancer. J. Clin. Oncol., 33.","DOI":"10.1200\/jco.2015.33.3_suppl.626"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Konecny, G.E., Hendrickson, A.E.W., Jatoi, A., Burton, J.K., Paroly, J., Glaspy, J.A., Dowdy, S.C., and Slamon, D.J. (2016). A Multicenter Open-Label Phase II Study of the Efficacy and Safety of Palbociclib a Cyclin-Dependent Kinases 4 and 6 Inhibitor in Patients with Recurrent Ovarian Cancer. J. Clin. Oncol., 34.","DOI":"10.1200\/JCO.2016.34.15_suppl.5557"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S1160","DOI":"10.1016\/j.annonc.2020.08.2258","article-title":"LBA28 A Randomised Double-Blind Placebo-Controlled Phase II Trial of Palbociclib Combined with Letrozole (L) in Patients (Pts) with Oestrogen Receptor-Positive (ER+) Advanced\/Recurrent Endometrial Cancer (EC): NSGO-PALEO\/ENGOT-EN3 Trial","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"11345","DOI":"10.1158\/0008-5472.CAN-05-2159","article-title":"Mutually Exclusive Cyclin-Dependent Kinase 4\/Cyclin D1 and Cyclin-Dependent Kinase 6\/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma","volume":"65","author":"Ely","year":"2005","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","article-title":"A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4\/6","volume":"66","author":"Baughn","year":"2006","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2012-03-415984","article-title":"Prolonged Early G(1) Arrest by Selective CDK4\/CDK6 Inhibition Sensitizes Myeloma Cells to Cytotoxic Killing through Cell Cycle-Coupled Loss of IRF4","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 Study of Cyclin-Dependent Kinase (CDK)4\/6 Inhibitor Palbociclib (PD-0332991) with Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pan, D., and Richter, J. (2022). Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.819127"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 Inhibition with Tumor Responses by PD0332991 in Patients with Mantle Cell Lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2019.1612062","article-title":"A Phase I Trial of Palbociclib plus Bortezomib in Previously Treated Mantle Cell Lymphoma","volume":"60","author":"Martin","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A Phase 1 Trial of Ibrutinib plus Palbociclib in Previously Treated Mantle Cell Lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Wilde, L., Porazzi, P., Trotta, R., De Dominici, M., Palmisiano, N., Keiffer, G., Rancani, K., Yingling, K., Calabretta, B., and Kasner, M. (2023). A Phase I Study of the Combination of Palbociclib and Dexamethasone for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. Leuk. Res., 129.","DOI":"10.1016\/j.leukres.2023.107075"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-141572","article-title":"Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children\u2019s Oncology Group Pilot Study","volume":"136","author":"Raetz","year":"2020","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2021.11.013","article-title":"Palbociclib Dose Reductions and the Effect on Clinical Outcomes in Patients with Advanced Breast Cancer","volume":"60","author":"Ismail","year":"2021","journal-title":"Breast"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Watt, A.C., and Goel, S. (2022). Cellular Mechanisms Underlying Response and Resistance to CDK4\/6 Inhibitors in the Treatment of Hormone Receptor-Positive Breast Cancer. Breast Cancer Res., 24.","DOI":"10.1186\/s13058-022-01510-6"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Stanciu, I.-M., Parosanu, A.I., Orlov-Slavu, C., Iaciu, I.C., Popa, A.M., Olaru, C.M., Pirlog, C.F., Vrabie, R.C., and Nitipir, C. (2023). Mechanisms of Resistance to CDK4\/6 Inhibitors and Predictive Biomarkers of Response in HR+\/HER2-Metastatic Breast Cancer-A Review of the Literature. Diagnostics, 13.","DOI":"10.3390\/diagnostics13050987"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., Luca, F.D., Galardi, F., Risi, E., Santo, I.D., and Benelli, M. (2019). Mechanisms of Resistance to CDK4\/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00666"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Huang, J., Zheng, L., Sun, Z., and Li, J. (2022). CDK4\/6 Inhibitor Resistance Mechanisms and Treatment Strategies (Review). Int. J. Mol. Med., 50.","DOI":"10.3892\/ijmm.2022.5184"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 Mutations and Acquired Resistance to CDK 4\/6 Inhibitors in Patients with Metastatic Breast Cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"George, M.A., Qureshi, S., Omene, C., Toppmeyer, D.L., and Ganesan, S. (2021). Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693104"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2019.03.064","article-title":"Third-Generation CDK Inhibitors: A Review on the Synthesis and Binding Modes of Palbociclib, Ribociclib and Abemaciclib","volume":"172","author":"Poratti","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1021\/jm100571n","article-title":"4-(Pyrazol-4-Yl)-Pyrimidines as Selective Inhibitors of Cyclin-Dependent Kinase 4\/6","volume":"53","author":"Cho","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/pro.3135","article-title":"Palbociclib Can Overcome Mutations in Cyclin Dependent Kinase 6 That Break Hydrogen Bonds between the Drug and the Protein","volume":"26","author":"Maganhi","year":"2017","journal-title":"Protein Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Shan, H., Ma, X., Yan, G., Luo, M., Zhong, X., Lan, S., Yang, J., Liu, Y., Pu, C., and Tong, Y. (2021). Discovery of a Novel Covalent CDK4\/6 Inhibitor Based on Palbociclib Scaffold. Eur. J. Med. Chem., 219.","DOI":"10.1016\/j.ejmech.2021.113432"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10637-023-01385-0","article-title":"Development of Novel Palbociclib-Based CDK4\/6 Inhibitors Exploring the Back Pocket behind the Gatekeeper","volume":"41","author":"Li","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejmech.2016.07.020","article-title":"New Palbociclib Analogues Modified at the Terminal Piperazine Ring and Their Anticancer Activities","volume":"122","author":"Wang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Li, T., Zhou, A.D., Bai, L.F., Zhang, X.Y., Zhou, Y.T., Yang, H.L., Xu, L.T., Guo, X.Q., Zhu, X.Y., and Wang, D.J. (2022). Design, Synthesis, and Anticancer Activity of Three Novel Palbociclib Derivatives. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.959322"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Acosta, P., and Xiao, X. (2021). PROTACs to Address the Challenges Facing Small Molecule Inhibitors. Eur. J. Med. Chem., 210.","DOI":"10.1016\/j.ejmech.2020.112993"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in Vivo Protein Knockdown by Small-Molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/14756366.2022.2074414","article-title":"Recent Advances in IAP-Based PROTACs (SNIPERs) as Potential Therapeutic Agents","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1039\/C9CC00163H","article-title":"PROTACs Suppression of CDK4\/6, Crucial Kinases for Cell Cycle Regulation in Cancer","volume":"55","author":"Zhao","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders","volume":"62","author":"Su","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1002\/anie.201901336","article-title":"Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6","volume":"58","author":"Jiang","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","article-title":"Selective Degradation of CDK6 by a Palbociclib Based PROTAC","volume":"29","author":"Rana","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Anderson, N.A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G.A., Rozier, C., and Benowitz, A.B. (2020). Selective CDK6 Degradation Mediated by Cereblon, VHL, and Novel IAP-Recruiting PROTACs. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127106"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2004-08-3168","article-title":"Small-Molecule XIAP Inhibitors Derepress Downstream Effector Caspases and Induce Apoptosis of Acute Myeloid Leukemia Cells","volume":"105","author":"Carter","year":"2005","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Delbue, D., Mendon\u00e7a, B.S., Robaina, M.C., Lemos, L.G.T., Lucena, P.I., Viola, J.P.B., Magalh\u00e3es, L.M., Crocamo, S., Oliveira, C.A.B., and Teixeira, F.R. (2020). Expression of Nuclear XIAP Associates with Cell Growth and Drug Resistance and Confers Poor Prognosis in Breast Cancer. Biochim. Biophys. Acta Mol. Cell Res., 1867.","DOI":"10.1016\/j.bbamcr.2020.118761"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Pu, C., Liu, Y., Deng, R., Xu, Q., Wang, S., Zhang, H., Luo, D., Ma, X., Tong, Y., and Li, R. (2023). Development of PROTAC Degrader Probe of CDK4\/6 Based on DCAF16. Bioorg. Chem., 138.","DOI":"10.1016\/j.bioorg.2023.106637"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Kappel, C., Elliott, M.J., Kumar, V., Nadler, M.B., Desnoyers, A., and Amir, E. (2024). Comparative Overall Survival of CDK4\/6 Inhibitors in Combination with Endocrine Therapy in Advanced Breast Cancer. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-53151-8"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Desnoyers, A., Nadler, M.B., Kumar, V., Saleh, R., and Amir, E. (2020). Comparison of Treatment-Related Adverse Events of Different Cyclin-Dependent Kinase 4\/6 Inhibitors in Metastatic Breast Cancer: A Network Meta-Analysis. Cancer Treat. Rev., 90.","DOI":"10.1016\/j.ctrv.2020.102086"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Cejuela, M., Gil-Torralvo, A., Castilla, M.\u00c1., Dom\u00ednguez-Cejudo, M.\u00c1., Falc\u00f3n, A., Benavent, M., Molina-Pinelo, S., Ruiz-Borrego, M., and Bofill, J.S. (2023). Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108488"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Gehrchen, M.L., Berg, T., Garly, R., Jensen, M.-B., E\u00dfer-Naumann, S., R\u00f8nlev, J.D., Nielsen, H.M., Knoop, A., and K\u00fcmler, I. (2024). Real-World Effectiveness of CDK 4\/6 Inhibitors in Estrogen-Positive Metastatic Breast Cancer. BJC Rep., 2.","DOI":"10.1038\/s44276-024-00070-w"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"TPS1120","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1120","article-title":"ARV-471, an Estrogen Receptor (ER) PROTACdegrader, Combined with Palbociclib in Advanced ER+\/Human Epidermal Growth Factor Receptor 2\u2013Negative (HER2-) Breast Cancer: Phase 1b Cohort (Part C) of a Phase 1\/2 Study","volume":"40","author":"Hamilton","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: A Phase III Study of Vepdegestrant, a PROTAC ER Degrader, versus Fulvestrant in ER+\/HER2- Advanced Breast Cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Futur. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem.\u2014Int. Ed."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Mullard, A. (2019). First Targeted Protein Degrader Hits the Clinic. Nat. Rev. Drug Discov.","DOI":"10.1038\/d41573-019-00043-6"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis Targeting Chimeras (PROTACs) in \u201cbeyond Rule-of-Five\u201d Chemical Space: Recent Progress and Future Challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/22\/5334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:10Z","timestamp":1760113870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/22\/5334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":124,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["molecules29225334"],"URL":"https:\/\/doi.org\/10.3390\/molecules29225334","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}